… Results from a previous phase 3 study showed efficacy of the … In the initial phase 3 study,
infants aged 6–12 weeks and children aged 5–17 months were randomly assigned (1:1:1) to …

… In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy … First results from large pilot
implementation in Africa show … from a phase 3 trial (NCT01148459) in children with WHO stage 1 …

… children (age 5–17 months old at first vaccination) from the RTS,S/AS01 E phase 3 clinical
trial who received 3 … that this could have an impact on protective immunity to malaria [35]. Little …

… in infants and children in Africa: final results of a phase 3, … with RTS,S/AS01 E during the
first 3 years of the study, all of whom … recorded in the RTS,S/AS01 E phase 3 trial were chance …

… was observed during the first 2–3 days after RTS,S/AS01 vaccination in children 5 months
or … , no significant effect of RTS,S/AS01 vaccination on all-cause mortality was noted in our …

… The evidence base included phase 3 trials in seven African … dose in infants and children in
Africa: final results of a phase 3, … incidence was highest during the first year, and the higher …

… children 5–17 months of age were followed for median 48 months. The primary aim of the
Phase 3 trial was to assess RTS,S/AS01 … that provide other vaccines to African children at no …

… RTS,S/AS01 malaria vaccine was assessed in a phase 3 … Here, we report results of
RTS,S/AS01 vaccination in a small … all children who had received the first 3 doses of RTS,S/AS01, …

… was evaluated in a large phase 3 trial in 7 African countries in … malaria cases in the phase
3 trial RTS,S/AS01 suggests considerable individual health benefits for the vaccinated child. …

… efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first
results of an ongoing trial assessing different fractional-dose regimens in children, in natural …